Anthony Mega

2.7k total citations · 1 hit paper
70 papers, 1.3k citations indexed

About

Anthony Mega is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Anthony Mega has authored 70 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Pulmonary and Respiratory Medicine, 30 papers in Oncology and 21 papers in Surgery. Recurrent topics in Anthony Mega's work include Prostate Cancer Treatment and Research (22 papers), Bladder and Urothelial Cancer Treatments (20 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Anthony Mega is often cited by papers focused on Prostate Cancer Treatment and Research (22 papers), Bladder and Urothelial Cancer Treatments (20 papers) and Cancer Immunotherapy and Biomarkers (11 papers). Anthony Mega collaborates with scholars based in United States, France and Netherlands. Anthony Mega's co-authors include Howard Safran, Alain C. Mita, Jeffrey R. Infante, Karen Kelly, Carolyn D. Britten, James L. Gulley, Manish R. Patel, Alain Ravaud, Ding Wang and Andrea B. Apolo and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Anthony Mega

62 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

2017 466 citations Anthony Mega, Howard Safran et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anthony Mega United States	20	645	477	329	214	176	70	1.3k
Jeremy Lewin Australia	20	501 0.8×	225 0.5×	430 1.3×	361 1.7×	88 0.5×	100	1.3k
Andrew Jacobs United States	17	485 0.8×	229 0.5×	217 0.7×	160 0.7×	265 1.5×	29	1.2k
Emerson A. Lim United States	18	402 0.6×	210 0.4×	164 0.5×	167 0.8×	129 0.7×	66	1.0k
Bradley A. Schiff United States	25	895 1.4×	867 1.8×	697 2.1×	350 1.6×	142 0.8×	70	2.4k
Giovanni Pappagallo Italy	25	534 0.8×	622 1.3×	570 1.7×	284 1.3×	45 0.3×	108	1.8k
David M. Neskey United States	27	801 1.2×	651 1.4×	397 1.2×	490 2.3×	165 0.9×	67	2.0k
William Foo China	19	1.3k 2.0×	960 2.0×	547 1.7×	185 0.9×	241 1.4×	30	2.4k
Laurie Tuason United States	16	467 0.7×	300 0.6×	333 1.0×	149 0.7×	221 1.3×	27	1.1k
Marta Podda Italy	23	336 0.5×	241 0.5×	509 1.5×	384 1.8×	58 0.3×	97	1.6k
PHM de Mulder Netherlands	17	504 0.8×	716 1.5×	298 0.9×	273 1.3×	62 0.4×	27	1.2k

Countries citing papers authored by Anthony Mega

Since Specialization

Citations

This map shows the geographic impact of Anthony Mega's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthony Mega with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthony Mega more than expected).

Fields of papers citing papers by Anthony Mega

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthony Mega. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthony Mega. The network helps show where Anthony Mega may publish in the future.

Co-authorship network of co-authors of Anthony Mega

This figure shows the co-authorship network connecting the top 25 collaborators of Anthony Mega. A scholar is included among the top collaborators of Anthony Mega based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthony Mega. Anthony Mega is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Posada, Jessica M., Evgeny Yakirevich, Ashish M. Kamat, et al.. (2024). Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2. Modern Pathology. 37(3). 100424–100424. 8 indexed citations

Wang, Hanzhang, Ali Amin, Joanne Lee, et al.. (2024). Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management. Urologic Oncology Seminars and Original Investigations. 42(5). 144–154. 2 indexed citations

Khaleel, Sari, et al.. (2023). “Shared decision-making” for prostate cancer screening: Is it a marker of quality preventative healthcare?. Cancer Epidemiology. 88. 102492–102492. 3 indexed citations

Amin, Ali, et al.. (2023). 443 Pembrolizumab for BCG refractory non-muscle invasive bladder cancer yields poor recurrence-free survival and high toxicity in patients. SHILAP Revista de lepidopterología. A492–A492.

Souza, André De, Dragan Golijanin, Adam J. Olszewski, et al.. (2023). Abstract CT158: BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC). Cancer Research. 83(8_Supplement). CT158–CT158. 1 indexed citations

Stein, Mark N., Lawrence Fong, Ronald Tutrone, et al.. (2022). ADXS31142 Immunotherapy ± Pembrolizumab Treatment for Metastatic Castration-Resistant Prostate Cancer: Open-Label Phase I/II KEYNOTE-046 Study. The Oncologist. 27(6). 453–461. 28 indexed citations

Pereira, Jorge, Dragan Golijanin, Ali Amin, et al.. (2019). The natural history of renal cell carcinoma with isolated lymph node metastases following surgical resection from 2006 to 2013. Urologic Oncology Seminars and Original Investigations. 37(12). 932–940. 4 indexed citations

Stein, Mark N., Lawrence Fong, Ronald Tutrone, et al.. (2019). Abstract CT098: KEYNOTE-046: Effects of ADXS-PSA with or without pembrolizumab on survival and antigen spreading in metastatic, castration-resistant prostate cancer patients. Cancer Research. 79(13_Supplement). CT098–CT098. 2 indexed citations

Kim, Simon P., Ali Amin, Christopher Tucci, et al.. (2019). Clinically node-positive (cN+) urothelial carcinoma of the bladder treated with chemotherapy and radical cystectomy: Clinical outcomes and development of a postoperative risk stratification model. Urologic Oncology Seminars and Original Investigations. 38(3). 76.e19–76.e28. 12 indexed citations

10.

Brito, Joseph, Jorge Pereira, Daniel M. Moreira, et al.. (2018). The association of lymph node dissection with 30-day perioperative morbidity among men undergoing minimally invasive radical prostatectomy: analysis of the National Surgical Quality Improvement Program (NSQIP). Prostate Cancer and Prostatic Diseases. 21(2). 245–251. 6 indexed citations

11.

Pereira, Jorge, Gyan Pareek, Zheng Zhang, et al.. (2018). The Perioperative Morbidity of Transurethral Resection of Bladder Tumor: Implications for Quality Improvement. Urology. 125. 131–137. 23 indexed citations

12.

Leone, Andrew, Boris Gershman, Colin R. Butler, et al.. (2015). Atypical small acinar proliferation (ASAP): Is a repeat biopsy necessary ASAP? A multi-institutional review. Prostate Cancer and Prostatic Diseases. 19(1). 68–71. 26 indexed citations

13.

Yakirevich, Evgeny, Siraj M. Ali, Anthony Mega, et al.. (2015). A Novel SDHA-deficient Renal Cell Carcinoma Revealed by Comprehensive Genomic Profiling. The American Journal of Surgical Pathology. 39(6). 858–863. 47 indexed citations

14.

Reagan, John L., Alan G. Rosmarin, James N. Butera, et al.. (2011). Phase I trial examining addition of gemcitabine to CHOP in intermediate grade NHL. Cancer Chemotherapy and Pharmacology. 68(4). 1075–1080. 1 indexed citations

15.

Butera, James N., et al.. (2007). Are we training our fellows adequately in delivering bad news to patients? A survey of hematology/oncology program directors. Journal of Clinical Oncology. 25(18_suppl). 9023–9023. 2 indexed citations

16.

Squire, Sarah, et al.. (2006). An Unusual Case of Gemcitabine-Induced Radiation Recall. American Journal of Clinical Oncology. 29(6). 636–636. 22 indexed citations

17.

Barnett, Janine, et al.. (2005). Lack of bleeding in patients with severe factor VII deficiency. American Journal of Hematology. 78(2). 134–137. 24 indexed citations

18.

Mylonakis, Eleftherios, Anthony Mega, & Fred J. Schiffman. (1999). What do program directors in internal medicine think about international medical graduates? Results of a pilot study. Academic Medicine. 74(4). 452–452. 6 indexed citations

19.

Mylonakis, Eleftherios, Brian P. Dickinson, Maria D. Mileno, et al.. (1999). Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: Complete remission associated with highly active antiretroviral therapy. American Journal of Hematology. 60(2). 164–166. 35 indexed citations

20.

Ramratnam, Bharat, et al.. (1997). Determinants of Case Selection at Morning Report. Journal of General Internal Medicine. 12(5). 263–266. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact